COMMUNIQUÉS West-GlobeNewswire

Pascal Biosciences Discovers Cannabinoids Activate the Major Histocompatibility Complex to Aid Cancer Treatment
23/09/2019
VANCOUVER, British Columbia, and SEATTLE, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. ( TSX.V:PAS ) (“Pascal” or the “Company”) today revealed the mechanism whereby cannabinoids may directly aid in cancer [...]
Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope
23/09/2019
NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into [...]
resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019
23/09/2019
BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related [...]
Auransa Presents New Preclinical Data on AU-409, a Novel, AI-Derived Drug Candidate for the Treatment of Hepatocellular Carcinoma
23/09/2019
Oral Presentation at the 13th Annual Conference of the International Liver Cancer Association Highlights Promising Antitumor Activity in Preclinical Cancer Model and HCC Cell Lines PALO ALTO, Calif., Sept. 23, 2019 ( [...]
Novo Nordisk A/S – Share repurchase programme
23/09/2019
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 23 September 2019 – On 9 August 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the [...]
BeyondSpring’s Plinabulin Continues to Build on Superior Product Profile in Breast Cancer Trial for Neutropenia Prevention
23/09/2019
Data to be Presented at ESMO Congress 2019 in Barcelona NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer [...]
Passage Bio Grows Management Team with Chief Medical Officer and General Counsel Appointments
23/09/2019
Gary Romano, M.D., Ph.D joins as chief medical officer from Janssen R&D and Edgar (Chip) Cale, J.D., joins as general counsel from GlaxoSmithKline PHILADELPHIA, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a [...]
Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NY
23/09/2019
HOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, [...]
ORYZON Updates on New Activities
23/09/2019
To present at upcoming international conference - ESMO-2019 in Barcelona, Spain - 19th Annual Biotech in Europe Investment Forum in Basel, Switzerland - 4th Annual MarketsandMarkets Epigenetics Congress in London, UK - [...]
Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism
23/09/2019
Results of a Phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism were presented at the American Society for Bone and Mineral Research Annual Meeting Data suggest favorable pharmacologic and [...]
Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress
23/09/2019
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical [...]
Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors
23/09/2019
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and [...]
ALR Technologies Creates Algorithm to Support Therapy Advancement for Non-Insulin Dependent (NID) Diabetes Patients
23/09/2019
ALRT’s comprehensive diabetes management system now provides decision support for healthcare providers treating non-insulin dependent type 2 diabetes patients RICHMOND, Va., Sept. 23, 2019 (GLOBE NEWSWIRE) -- ALR [...]
Immutep to Receive £4M Milestone Payment From GSK
23/09/2019
SYDNEY, Australia, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune [...]
Qrons Announces Appointment of Derrick Chambers to Advisory Board
23/09/2019
Former NFL Player is Financial Literacy Advocate to NFL Players Association and NFL Alumni Association NEW YORK, NY, Sept. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Qrons Inc. (OTCQB: QRON), an emerging [...]
AMAG Files Definitive Consent Revocation Statement and Sends Letter to Shareholders
23/09/2019
Details Caligan Partners’ Reckless Business Ideas and Inexperienced Director Nominees Urges Shareholders to Sign and Return AMAG’s GREEN Consent Revocation Card WALTHAM, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- AMAG [...]
CareDx’s KidneyCare iBox Technology Clinically Validated in BMJ Publication
23/09/2019
Artificial Intelligence algorithm predicts long-term kidney transplant outcomes BRISBANE, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the [...]
Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Funding and Support for ELX-02 U.S. Phase 2 Clinical Trial
23/09/2019
CF Foundation and Eloxx to form joint program advisory group focused on the development of ELX-02 for cystic fibrosis Eloxx plans to conduct the U.S. portion of the Phase 2 clinical trial at Cystic Fibrosis Therapeutics [...]
Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019
23/09/2019
FDA agrees with Company’s proposed changes to the statistical analysis plan for the REST-ON Phase 3 study for once-nightly sodium oxybate, FT218 Reduces estimated time to completion by up to 12 months; now expected to [...]

Pages